USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: IMMPORT THERAPEUTICS, INC.
Address: 1 Technology Drive, Suite E309
IRVINE, CA
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,200,388.00 6
SBIR Phase II $5,333,268.00 2
STTR Phase I $599,255.00 1

Award List:

Vaccinia Proteome Affinity Reagents From Phage Display

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Philip L. Felgner
Award Amount: $995,030.00
Abstract:
DESCRIPTION (provided by applicant): The need for nimble technology platforms to counter bioterrorism threats motivates the research proposed here. In this project, reagents with high affinity and specificity for vaccinia virus proteins will be selected from phage-displayed libraries. The ultimate… More

Scanning the P. falciparum proteome for vaccine antigens

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Philip L. Felgner
Award Amount: $598,668.00
Abstract:
DESCRIPTION (provided by applicant): The abundance of genomic data from infectious microorganisms provides a wealth of information that may now be used to identify antigen targets for subunit vaccine development. Here we propose a strategy employing bioinformatics together with high throughput… More

Adjuvants for Agile Vaccine Development

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Philip L. Felgner
Award Amount: $886,845.00
Abstract:
DESCRIPTION (provided by applicant): Because of the potential bioterrorism threat, the development of safe and effective vaccines against the infectious microorganisms on the select agents list is a national and worldwide goal. In some cases there are vaccines in existence but they are considered… More

Development of a multiplex serodiagnostic assay for B burgdorferi infection

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Philip L. Felgner
Award Amount: $525,836.00
Abstract:
DESCRIPTION (provided by applicant): Lyme disease (LD), the most commonly reported arthropod-borne infection in the United States and Europe, is increasing in its distribution on both continents. The commercial failure of the LD vaccine in the U.S. means t hat timely detection and treatment of cases… More

Scanning Chlamydia proteome for vaccine antigens

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF CALIFORNIA, IRVI
Principal Investigator: Luis M. Delamaza
Award Amount: $599,255.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Throughout the world Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen. In areas with poor sanitary conditions C. trachomatis causes trachoma the most common cause of preventable blindness in the world. A majority of the genital C.… More

Seriodiagnostic arrays for biodefense and emerging infectious diseases

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $2,991,855.00
Abstract:
DESCRIPTION (provided by applicant): In Phase I of this SBIR, ImmPORT Therapeutics and the UCI Proteomics Core developed a high throughput gene cloning and protein expression platform that allowed the proteomes of any sequenced infectious agent to be expre ssed and printed onto microarray chips.… More

Antibodies to malaria blood stages in mixed-species infections

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $594,009.00
Abstract:
DESCRIPTION (provided by applicant): Malaria remains one of the most prevalent and lethal human infectious diseases worldwide. Of the four species of malaria parasites that infect humans (Plasmodium falciparum, P. vivax, P. ovale, and P. malariae), P. falc iparum and P. vivax are the most common. P.… More

Protective biomarkers for the development of vaccines against malaria

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Philip L. Felgner – 949-824-1407
Award Amount: $2,341,413.00
Abstract:
DESCRIPTION (provided by applicant): For the Phase I SBIR grant we constructed a Plasmodium falciparum (Pf) 3D7 protein microarray containing 2,320 individual polypeptides representing 1,200 known and hypothetical proteins, or ~23 % of the entire Pf proteome. We showed that the individual proteins… More

Integrated Microfluidic Platform for Point-of-Care Serodiagnostics

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Xiaowu Liang – 949-679-4068
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): We aim to develop a fully integrated microfluidic immunodiagnostic platform utilizing a novel air-liquid cavity acoustic transducer (ALCAT) technology pioneered in the lab of Dr Abe Lee. The diagnosis platform is basedon the well-established clinical diagnostic… More